




HEMOLYTIC DISEASE OF NEWBORN AND FETUS HDN



WHAT IS HDN?

- ✗ Destruction of the RBCs of the fetus and newborn by antibodies produced by the mother
- ✗ Only IgG antibodies are involved because it can cross the placenta (not IgA or IgM)






Amniotic fluid

Placenta
(see detail
opposite)

Fetus

Umbilical cord

Uterine wall



PATHOPHYSIOLOGY

- ✗ Although transfer of maternal antibodies is good, transfer of antibodies involved in HDN are directed against antigens on fetal RBCs inherited by the father
- ✗ Most often involves antigens of the Rh and ABO blood group system, but can result from any blood group system
- ✗ Remember: The fetus is **POSITIVE** for an antigen and the mother is **NEGATIVE** for the same antigen
- ✗ The mother is sensitized to the foreign antigen present on her child's RBCs usually through some seepage of fetal RBCs (fetomaternal hemorrhage) or a previous transfusion
- ✗ HDN occurs when these antibodies cross the placenta and react with the fetal RBCs.

ABO HDN

- ✗ ABO incompatibilities are the most common cause of HDN but are less severe.
- ✗ About 1 in 5 pregnancies are ABO-incompatible.
- ✗ 65% of HDN are due to ABO incompatibility.
 - ✗ Usually, the mother is type **O** and the child has the **A** or **B** antigen...**Why?**
- ✗ Group **O** individuals have a high titer of **IgG** anti-A,B in addition to having **IgM** anti-A and anti-B.
- ✗ ABO HDN can occur during the FIRST pregnancy prior sensitization is not necessary

ABO HDN

- ✗ ABO HDN is less severe than Rh HDN because there is less RBC destruction.
- ✗ Fetal RBCs are less developed at birth, so there is less destruction by maternal antibodies.
- ✗ When delivered, infants may present with mild **anemia** or normal hemoglobin levels.
- ✗ Most infants will have **hyperbilirubinemia** and jaundice within 12 to 48 hours after birth


DIAGNOSIS OF ABO HDN

- ✗ Infant presents with **jaundice** 12-48 hrs after birth.
- ✗ Testing done after birth on cord blood samples.

TREATMENT OF ABO HDN


- ✗ Only about 10% require therapy
- ✗ **Phototherapy** is sufficient, Phototherapy is exposure to artificial or sunlight to reduce jaundice.
- ✗ Rarely is exchange **transfusion** needed, Exchange transfusion involves removing newborn's RBCs and replacing them with normal fresh donor cells

PHOTOTHERAPY



Fluorescent blue light in the 420-475 nm range

EXCHANGE TRANSFUSION




WHAT TYPE OF BLOOD TO GIVE FETUS:


- ✗ STORCH negative
- ✗ Irradiated
- ✗ Fresh Whole Blood (to avoid $\uparrow\text{Ca}^{++}$)
- ✗ Maternal blood if possible
- ✗ Leukoreduced

RH HDN

- ✗ Mother is d negative (d/d) and child is D positive (D/d).
- ✗ Most severe form of HDN.
- ✗ 33% of HDN is caused by Rh incompatibility.
- ✗ Sensitization usually occurs very late in pregnancy, so the first Rh-positive child is not affected.
- ✗ Bleeds most often occur at delivery.
- ✗ Mother is sensitized.
- ✗ Subsequent offspring that are D-positive will be affected



Rh-negative woman and Rh-positive man conceive a child



Rh-negative woman with Rh-positive fetus



Cells from Rh-positive fetus enter woman's bloodstream



Woman becomes sensitized—antibodies (⬠+) form to fight Rh-positive blood cells




In the next Rh-positive pregnancy, maternal antibodies attack fetal red blood cells

About 1 in 10 pregnancies involve an Rh-negative mother and an Rh-positive father

During delivery, Rh antigens enter mother's circulation through breaks in the placenta


Mother makes anti-Rh antibodies



(a) First pregnancy

Mother has anti-Rh antibodies

Anti-Rh antibodies cross the placenta and destroy fetal blood cells



(b) Subsequent pregnancy


FETOMATERNAL HEMORRHAGE

- ✘ Sensitization occurs as a result of seepage of fetal cells into maternal circulation as a result of a fetomaternal hemorrhage
 - Placental membrane rupture (7%)
 - Trauma to abdomen
 - Delivery (>50%)
 - Amniocentesis
 - Abortion

FETAL
CIRCULATION



Positive cells



MATERNAL
CIRCULATION



Invading fetal
(positive) cells


RISK

- ✗ Rh-negative women can be exposed to Rh-Positive cells through **transfusion** or **pregnancy**
- ✗ Each individual varies in their immune response (depends on amount exposed to)
 - + 85% transfused with 200 mL Rh-positive cells will develop anti-D
 - + There is only about a 9% chance that Rh-neg mothers pregnant with an Rh-positive child will be stimulated to produce anti-D (without RhIg)

PATHOGENESIS


- ✗ Maternal IgG attaches to antigens on fetal cells
- ✗ Sensitized cells are removed by macrophages in spleen.
- ✗ Destruction depends on antibody titer and number of antigen sites.
- ✗ IgG has half-life of 25 days, so the condition can range from days to weeks.
- ✗ RBC destruction and anemia cause bone marrow to release erythroblasts, hence the name “erythroblastosis fetalis”)

INCREASED IMMATURE RBCS




PATHOGENESIS

- ✗ When erythroblasts are used up in the bone marrow, **erythropoiesis** in the spleen and liver are increased
 - + **Hepatosplenomegaly** (enlarged liver & spleen)
 - + **Hypoproteinemia** (from decreased liver function) leads to cardiac failure edema, etc called “Hydrops fetalis”



BILIRUBIN

- ✗ Hemoglobin is metabolized to bilirubin
 - + Before birth, “**indirect**” bilirubin is transported across placenta and conjugated in maternal liver. “**direct**” where it is excreted
 - + After birth, the newborn liver is unable to conjugate the bilirubin
 - ✗ Unconjugated (“indirect”) bilirubin can reach toxic levels (18-20 mg/dL)
 - ✗ This is called **kernicterus** and can lead to permanent brain damage



DIAGNOSIS & MANAGEMENT

- × Serologic Testing (mother & newborn)
 - × Amniocentesis and Cordocentesis
 - × Intrauterine Transfusion
 - × Early Delivery
- × Phototherapy & Newborn Transfusions

SEROLOGIC TESTING ON MOTHER

× ABO and Rh testing


- + Test for D antigen (test for weak D if initially negative)

× Antibody Screen

- + To test detect for IgG alloantibodies that react at 37°C
- + If negative, repeat before RhIg therapy and/or if patient is transfused or has history of antibodies (3rd trimester)

× Antibody ID

- + Weakly reacting anti-D may be due to FMH or passively administered anti-G (RhIg)
- + If antibody is IgG, anti-D is most common followed by anti-K and other Rh antibodies




SEROLOGIC TESTING (CONT'D)

× Antibody titration

- + Antibody concentration is determined by antibody titration.
- + Mother's serum is diluted to determine the highest dilution that reacts with reagent RBCs at 37°C (60 min).
- + First sample is frozen and run with later specimens.
- + Testing is repeated at 16 and 22 weeks and 1- to 4- week.
 - × A titer of 16-32 is significant
 - × >16 should be repeated at 18-20 weeks' gestation
 - × >32 indicates a need for amniocentesis or cordocentesis between 18-24 weeks' gestation
 - × <32 is repeated every 4 weeks (18-20 weeks) and every 2-4 weeks (third trimester).


AMNIOCENTESIS & CORDOCENTESIS

- ✗ About 18-20 weeks' gestation
- ✗ Cordocentesis takes a sample of umbilical vessel to obtain blood sample
- ✗ Amniocentesis assesses the status of the fetus using amniotic fluid
 - + Fluid is read on a spectrophotometer (350-700 nm)
 - + Change in optical density (ΔOD) above the baseline of 450 nm is the bilirubin measurement




WHAT TO DO?

- ✗ Intrauterine transfusion is done :
 - Removes bilirubin
 - Removes sensitized RBCs
 - Removes antibody



Intrauterine transfusion



A fetus may receive a blood transfusion through the umbilical vein in the placenta

OTHER TREATMENTS

✗ Early Delivery

- + If labor is induced, fetal lung maturity must be determined using the lecithin/sphingomyelin (L/S) ratio (thin layer chromatography) to avoid respiratory distress syndrome

✗ Phototherapy (after birth)

- + Change unconjugated bilirubin to biliverdin
- + May avoid the need for exchange transfusion

✗ Newborn transfusion

- + Small aliquots of blood (PediPak)
- + Corrects anemia

PREVENTION

- ✗ RhIg (RhoGAM®) is given to the mother to prevent immunization to the D antigen
 - + “Fools” mom into thinking she has the antibody
 - + RhIg (1 dose) is given at 28 weeks’ gestation
 - + RhIg attaches to fetal RBCs in maternal circulation and are removed in maternal spleen; this prevents alloimmunization by mother

POSTPARTUM ADMINISTRATION OF RHIG


- ✗ Another dose of RhIg should be given to the mother within 72 hours of delivery (even if stillborn)
 - + Mother should be D negative
 - + Newborn should be D positive or weak D
 - + About 10% of the original dose will be present at birth, so it's important to give another dose to prevent immunization

DOSE

- ✖ Each vial of RhIg contains enough anti-D for protect
 - + One vial contains 300 µg of anti-D
 - + Given intramuscularly or intravenously
- + Massive fetomaternal hemorrhage (>30 mL) requires more than one vial

ROSETTE TEST

- ✗ A qualitative measure of fetomaternal hemorrhage



Fetomaternal Hemorrhage:

- <1 rosette per 3 lpf = 1 dose of RhIg
- >1 rosette per 3 lpf = Quantitate bleed

CONSIDERATIONS

- ✗ RhIg is of no benefit once a person has formed anti-D
- ✗ It is VERY important to distinguish the presence of anti-D as:
 - Residual RhIg from a previous dose OR
 - True immunization from exposure to D+ RBCs
- RhIg is not given to the mother if the infant is D negative (and not given to the infant)

